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MicroRNAs (miRNAs) are important regulators of gene expression and like any other
gene, their coding sequences are subject to genetic variation. Variants in miRNA
genes can have profound effects on miRNA functionality at all levels, including miRNA
transcription, maturation, and target specificity, and as such they can also contribute to
disease. The impact of variants in miRNA genes is the focus of the present review. To
put these effects into context, we first discuss the requirements of miRNA transcripts
for maturation. In the last part an overview of available databases and tools and
experimental approaches to investigate miRNA variants related to human disease is
presented.
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Introduction
miRNAs are short, non-protein-coding RNA molecules that mediate post-transcriptional
regulation by aﬀecting mRNA stability and translational repression or activation (Vasudevan et al.,
2007; Filipowicz et al., 2008).
miRNAs were ﬁrst discovered in 1993 in Caenorhabditis elegans (Lee et al., 1993). In 2000–
2001 many other miRNA genes were identiﬁed in C. elegans and miRNAs were shown to be
widely present in other species (Pasquinelli et al., 2000; Lagos-Quintana et al., 2001; Lau et al.,
2001; Lee and Ambros, 2001). Since then, given their impact on expression, miRNAs have
been extensively studied and the miRBase database, the central miRNA sequence repository,
continues to expand, collecting novel miRNA genes in a wide variety of species (Kozomara
and Griﬃths-Jones, 2014). Even in the human genome, with 1881 precursors and 2588 mature
miRNA sequences deposited in miRBase version 21, many novel miRNA genes are being
identiﬁed and published continuously (Friedländer et al., 2014; Cheng et al., 2015; Londin
et al., 2015). Despite the extensive research, we are still uncovering aspects of the miRNA
maturation process and we have to date only a limited understanding of the functions of speciﬁc
miRNAs.
miRNAs add a layer of complexity to gene regulation. They target transcripts mainly by
complementarity to the seed region, nucleotides (nt) 2–7 of the mature miRNA molecule
(Bartel, 2009). This minimal requirement for complementarity results in targeting of many
mRNAs by a single miRNA and targeting of one mRNA by several miRNAs (Lim et al.,
2005; Peter, 2010; Wu et al., 2010). In addition, miRNAs can have sequence and length
variability (isomiRs), potentially resulting in altered targeting capacity and/or speciﬁcity. One
of the aspects that further inﬂuences the complexity of the miRNA repertoire are genetic
variants.
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This review provides an overview of the current knowledge
of the inﬂuence of genetic variants on miRNA biogenesis
and function. First, miRNA biogenesis and requirements of
the miRNA processing enzymes are described, followed by a
discussion of isomiRs and their functional implications. In the
second part, we highlight the eﬀect of genetic variants on
the expression and functioning of miRNAs. In the last part,
approaches that are used to identify miRNAs involved in diseases
are discussed, with a focus on genetic strategies. Furthermore, we
present available tools, databases, and experimental approaches
to aid functional characterization studies of disease-associated
miRNA variants.
MicroRNA Biogenesis and Generation
of IsomiRs
miRNA genes can be classiﬁed in several categories according to
their location in the genome. A majority of the currently known
human miRNA genes deposited in miRBase are intergenic (68%).
Of the intragenic miRNAs, most are intronic (12% of all genes).
The remaining genes are located in repeats, lncRNAs, UTRs, or
coding regions of host genes (Londin et al., 2015). miRNA genes
are often located close to other miRNA genes in so-called clusters.
miRNAs located in host genes or clustered with other miRNAs
can be cotranscribed, which is supported by good correlation
of their expression patterns for several genes (Baskerville and
Bartel, 2005). Alternatively, intronic miRNAs can be transcribed
independently from their host gene and polycistronic miRNA
transcripts can undergo alternative splicing to yield speciﬁc
miRNA expression (Ramalingam et al., 2014).
In the canonical biogenesis pathway, primary miRNA
transcripts (pri-miRNAs) are cleaved in the nucleus by the
Microprocessor complex, a complex consisting of ribonuclease
Drosha and its cofactor DGCR8, to release the shorter precursor
miRNA (pre-miRNA). This precursor molecule is transported to
the cytosol by the nucleocytoplasmic transport protein Exportin-
5, where it is cleaved by the ribonuclease Dicer to result in
a mature miRNA duplex consisting of the mature 5p and
3p strands. The duplex is loaded onto an Argonaute protein,
the core component of the RNA induced silencing complex
(RISC). One of the strands is discarded, while the other mediates
posttranscriptional regulation by base pairing to target mRNAs.
There are diﬀerent types of target sites. Canonical sites for
miRNA targeting are seedmatches (nt 2–7 of the mature miRNA)
with an adenine opposite from the ﬁrst nt of the mature miRNA
and/or complementarity to the eighth nt of the miRNA. This seed
match can be supplemented with complementarity to nt 13–16 (3′
supplementary sites). Extended sites of complementarity at the
3′ end of the miRNA can also compensate for seed mismatches
(3′ compensatory sites) (Bartel, 2009). Though a majority of the
miRNA-target interactions include seed matches, many non-seed
interactions are also observed (Helwak et al., 2013). Similarly,
though mRNAs are the predominant miRNA targets, 30% of all
miRNA targets are other classes of RNA, such as rRNA, tRNA,
snRNA, miRNA, lincRNA, and pseudogenes (Helwak et al.,
2013).
Mirtrons, miRNAs encoded within short introns of host genes,
bypass processing by the Microprocessor complex. By splicing
the mirtron is released and can be, if needed after 5′ or 3′ tail
trimming, transported to the cytosol to be further processed
by Dicer. In the study of Ladewig et al. (2012), 240 human
mirtrons were identiﬁed, indicating that bypassing Drosha is
not a rare phenomenon. Other non-canonical miRNA biogenesis
pathways have also been discovered and were recently reviewed
by Abdelfattah et al. (2014). In the next sections, we will focus
on the general miRNA characteristics and substrate requirements
of the key enzymes of the canonical miRNA maturation
pathway.
Maturation Enzyme Requirements
Microprocessor Complex
Drosha, a nuclear ribonuclease, is the enzyme that cleaves the
miRNA hairpin from the primary transcript, whereby it generates
a precursor with 3′ end overhangs of 2 nt (Lee et al., 2003). An
essential cofactor for its pri-miRNA processing activity is the
protein DGRC8. The complex containing Drosha and DGCR8,
also called the Microprocessor complex, is suﬃcient for pri-
miRNA processing (Denli et al., 2004; Gregory et al., 2004;
Han et al., 2004; Landthaler et al., 2004). The capacity of
DGCR8 to bind pri-miRNAs is necessary for Drosha cleavage
(Yeom et al., 2006). DCGR8 trimerizes upon binding of pri-
miRNAs and formation of this protein-pri-miRNA complex
may allow speciﬁc recognition of pri-miRNAs as opposed to
other types of RNA and trigger subsequent cleavage by Drosha
(Faller et al., 2010).
Several common features of pri-miRNAs were determined by
thermodynamic proﬁling of secondary structure predictions on a
set of human and ﬂy pri-miRNAs: the transcript contains a local
hairpin structure with an imperfectly paired stem of ∼33 base
pairs (bp), consisting of an upper stem (∼22 bp, region of the
mature miRNA duplex) and a lower stem (∼11 bp), a terminal
loop region and ﬂanking segments that are usually single-
stranded or have large bulges or internal loops (Han et al., 2006).
Essential requirements of pri-miRNAs for Drosha processing
were experimentally determined. The stem-loop structure within
the pri-miRNA needs to be larger than the pre-miRNA: it
needs an extended stem (i.e., the lower stem, ∼11 bp) and an
unstructured region ﬂanking the hairpin (Lee et al., 2003; Chen
et al., 2004; Zeng and Cullen, 2005; Zeng et al., 2005; Han et al.,
2006; Auyeung et al., 2013). In vitro cleavage assays showed
that Drosha was able to process pri-miR-30a and pri-miR-16-1
with as little as ∼20–25 nt of ﬂanking regions (Lee et al., 2003;
Han et al., 2004). However, for correct in vivo processing longer
ﬂanking regions are required (Chen et al., 2004). The presence of
a large unstructured terminal loop region is beneﬁcial for Drosha
processing, as reduction of the size of the predicted terminal loop
results in reduced processing (Zeng et al., 2005; Han et al., 2006;
Zhang and Zeng, 2010). These properties correspond with the in
silico determined characteristics of known miRNA hairpins.
Two diﬀerent models have been proposed to explain how
Drosha determines where to cleave the pri-miRNA. One
study proposed that the Microprocessor mainly determines the
distance from the terminal loop region of the hairpin and
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cleaves ∼22 bp upstream (Zeng et al., 2005). Another hypothesis
proposed that Drosha predominantly cleaves ∼11 bp away
from the junction between the lower hairpin stem and the
ﬂanking regions (Han et al., 2006). A recent study showed that
the complex determines the distance to both ssRNA–dsRNA
junctions and that both distances need to be optimal in order to
result in precise cleavage (Ma et al., 2013).
Next to the structural prerequisites of the hairpin, position-
speciﬁc sequence motifs present in the hairpin ﬂanking
segments of the primary transcript (UG motif, CNNC
motif) and in the loop region (UGU or GUG motif) can
enhance processing eﬃciency in human cells. Nearly 80%
of the human pri-miRNAs that are conserved between
human and mice contain at least one of these motifs
(Auyeung et al., 2013).
Exportin-5
The transport of pre-miRNAs from the nucleus to the cytosol
is mediated by Exportin-5 in the presence of cofactor RanGTP
(Yi et al., 2003; Bohnsack et al., 2004; Lund et al., 2004). The
RNA structure is the main determinant for precursor binding: a
stem of at least 18 bp and a blunt end or a 3′ overhang, such as
the overhang created by Drosha (Lee et al., 2003), is preferential
(Zeng and Cullen, 2004). Upon binding, the 3′ 2 nt overhang of
the precursor and a large part of the stem is bound by Exportin-5-
RanGTP in a sequence-independent manner, which protects the
precursor from degradation by nucleases (Bohnsack et al., 2004;
Zeng and Cullen, 2004; Okada et al., 2009).
Dicer
Dicer, a ribonuclease that processes dsRNA into duplexes
with a length of ∼22 nt, processes pre-miRNAs into mature
miRNA duplexes (Bernstein et al., 2001; Grishok et al., 2001;
Hutvágner et al., 2001; Ketting et al., 2001; Knight and Bass,
2001). Dicer cleaves its substrates gradually with a preference
to start at the termini of the RNA duplex and generates 2 nt
3′ overhangs (Zhang et al., 2002, 2004). The structure of the
termini contributes to the size of the end product, with 2 nt
3′ overhangs resulting in products less than 24 nt, while blunt
ends result in longer fragments (Vermeulen et al., 2005). Dicer
eﬃciency is aﬀected by several substrate parameters, such as
the size of the loop (in case of pre-miRNAs) and the sequence
and the size of the overhangs, with 3′ overhangs of 2 nt being
the most eﬃcient substrate for human Dicer (Vermeulen et al.,
2005; Lund and Dahlberg, 2006; Zhang and Zeng, 2010; Park
et al., 2011). Dicer binds both the 5′ and 3′ end of the precursor
molecule and mainly cleaves at a distance of 22 nt from the
5′ end (Park et al., 2011). The accuracy of the cleavage seems
to depend on the distance between this canonical cleavage site
and the nearest bulge or the terminal loop (Gu et al., 2012).
The Drosha-mediated generation of pre-miRNAs with a 3′
overhang of 2 nt and a stem of ∼22 bp thus provides suitable
substrates for Dicer. This results in the removal of the loop by
Dicer and acquirement of mature miRNA duplexes of ∼22 nt
bearing 2 nt overhangs at the 3′ end of both strands, on one
side generated by Drosha and at the other side generated by
Dicer.
Argonaute
The mature miRNA duplex is loaded onto an Argonaute protein
by the RISC loading complex. This complex matures to RISC
when one of the strands, termed the passenger strand, is removed
(Czech and Hannon, 2011). The other strand, termed the guide
strand, can then, in complex with Argonaute, target RNAs via
sequence complementarity for posttranscriptional regulation.
The process of strand selection is asymmetric: for many miRNAs
one of the strands is preferentially retained. This bias is in part
explained by the relative stability of the 5′ end of both strands,
where the strand with the lowest stability is preferentially retained
within RISC (Khvorova et al., 2003; Schwarz et al., 2003). Another
contributing factor is the sequence composition of the strands:
for human miRNA duplexes with a large diﬀerence in expression
between both strands, the highest expressed strand has a bias
toward a uracil at position 1 and a high purine content, while the
lower expressed strand has a bias toward a cytosine at position
1 and a high pyrimidine content (Hu et al., 2009). However, as
the dominant strand can vary between tissues (Cloonan et al.,
2011), other, yet unknown, factors than sequence and structure
of the miRNA duplex itself must be contributing to this variable
selection bias.
Proteins Involved in Regulation of
Biogenesis
In addition to the biogenesis key proteins described above,
a number of other proteins are known to be involved in
the regulation of miRNA biogenesis. The following examples
highlight the relevance of the terminal loop region in this
regulation. The ﬁrst example is the protein KSRP. This protein
binds directly to the terminal loop of a set of miRNAs and
enhances their processing by Drosha and Dicer (Trabucchi et al.,
2009). Another example is the regulation by Lin28 and terminal
uridyl transferase TUTase4. Lin28 binds a GGAG sequence motif
in the terminal loop of speciﬁc pre-miRNAs, including let-7
family members, upon which TUTase4 binds to the Lin28-pre-
miRNA complex and uridylates the 3′ end of the pre-miRNA.
This oligo-uridylation prevents processing by Dicer (Heo et al.,
2008, 2009; Hagan et al., 2009). In addition to the Lin28-mediated
inhibitory role of TUTase4, this enzyme (and other terminal
uridyl transferases) also mono-uridylates a subset of pre-let-7
family members and other miRNAs with a 3′ 1 nt overhang,
promoting Dicer processing (Heo et al., 2012). An overview of
all proteins involved in the regulation of miRNA biogenesis can
be found in Siomi and Siomi (2010).
IsomiR Repertoire
Mature miRNAs originating from one arm of a pre-miRNA
can have sequence and length heterogeneity in vivo, with
sequences and lengths closely related to, but diﬀerent from
the canonical miRNA sequence reported in miRBase. Such
alternative sequences are termed isomiRs (Morin et al., 2008).
Diﬀerent types of isomiRs have been observed: templated
additions or deletions at the 5′ and/or 3′ end of the miRNA,
non-templated additions at the 3′ end and substitutions within
the sequence (Landgraf et al., 2007; Morin et al., 2008;
Martí et al., 2010). Alternative processing by Drosha or
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Dicer, Dicer-independent Argonaute2-mediated cleavage and
exonuclease degradation of the 3′ terminus of miRNAs can be
a source of templated isomiR genesis. Non-templated changes
can be established by nucleotidyl transferases, posttranscriptional
editing or due to the presence of genetic variants within the
transcript (Morin et al., 2008; Cloonan et al., 2011; Neilsen et al.,
2012; Lee et al., 2013; Ma et al., 2013).
Since miRNAs target transcripts via imperfect sequence
complementarity, isomiRs with a changed sequence for the
nucleotides contributing to the target speciﬁcity are expected
to aﬀect the target spectrum of the miRNA. Given that the
majority of miRNA-target interactions include matches to the
miRNA seed (Helwak et al., 2013), isomiRs with an altered seed
sequence, such as 5′ isomiRs, may have a large inﬂuence on
target speciﬁcity. Sets of isomiRs with an altered seed sequence
were predicted to gain the capacity to regulate many additional
genes and/or lose the capacity to regulate a subset of genes
compared to the canonical miRNA (Gong et al., 2012; Tan et al.,
2014). Gain or (partial) loss of function of isomiRs with altered
seed sequence and even of isomiRs with a preserved seed has
been conﬁrmed experimentally (Kawahara et al., 2007; Gong
et al., 2012; Chan et al., 2013; Tan et al., 2014). The size of the
eﬀect will, however, be largely determined by the absolute and
relative expression and stability of the isomiR compared to the
canonical miRNA in vivo and its binding eﬃciency to RISC,
which can also be aﬀected by the sequence variability (Chan et al.,
2013; Llorens et al., 2013). Alternatively, it has been suggested
that isomiRs, which often show a high expression correlation
with their canonical miRNAs, may function to regulate the
same pathways as the canonical miRNA and that the sequence
heterogeneity within isomiR populations may act to reduce oﬀ-
target eﬀects (Cloonan et al., 2011). The broader functional
implications of isomiRs, their contribution to gene expression
regulation and how their expression is controlled remains to be
further elucidated.
Impact of Genetic Variants on miRNA
Expression and Function
As presented above, miRNA transcripts need to fulﬁll structural
and sequence prerequisites in order to result in expression of
the correct mature miRNA sequence(s). Sequence variability in
miRNA genes can therefore inﬂuence both the expression level
as the functionality of the miRNA and consequently will result in
diﬀerential regulation of their target genes.
Large-scale in silico analyses of single nucleotide
polymorphisms (SNPs) in human miRNA genes have
demonstrated that miRNA genes have lower SNP densities
than their ﬂanking regions or the human genome (Saunders
et al., 2007; Gong et al., 2012; Han and Zheng, 2013). Within
the miRNA gene the mature sequence has a lower SNP density
than the precursor, with the seed having the lowest SNP density,
reﬂecting their functional importance. In addition, it was shown
that there is a negative correlation between the number of SNPs
a miRNA gene harbors and the number of diseases the miRNA is
associated with (Han and Zheng, 2013). This again highlights the
importance of genetic variants in miRNA genes related to their
function and their involvement in human diseases.
Genetic variants can aﬀect miRNAs on several levels.
Variants in miRNA promoter regions and other regulatory
regions may result in an altered transcription rate. Variants
in splice sites of the host gene (for intronic miRNAs) or of
the polycistron (clustered miRNAs) could result in aberrant
expression patterns. Next, variants within the miRNA transcript
can have an eﬀect on miRNA maturation in multiple aspects.
They can change the binding aﬃnity of the miRNA hairpin
to biogenesis enzymes or accessory proteins (sequence motifs
or structural motifs that are changed due to the modiﬁed
underlying sequence). Variants can lead to altered processing
accuracy or to changed frequency of alternative cleavage sites
of biogenesis enzymes. They can also lead to altered strand
loading bias into RISC. These changes in maturation can all
result in altered expression of the canonical miRNA and its
existing isomiRs, resulting in deregulation of target genes. It may
also result in production of novel isomiRs, which can lead to
altered functionality of the miRNA. Lastly, genetic variants within
the mature sequence can aﬀect target speciﬁcity by generating
isomiRs.
Given the potentially huge impact of genetic variants on
the tightly regulated miRNA repertoire, and the importance
of miRNA-mediated gene regulation, it is not surprising that
genetic variants have been found to be causal for or associated
with human diseases (Mencía et al., 2009; Hughes et al., 2011).
Variants in miRNA biogenesis enzymes and in miRNA binding
sites can also lead to impaired miRNA regulation. However, the
latter category of variants would likely have a smaller impact
than the former two categories, because only the targeting of
one gene by one miRNA would be disrupted in case the target
does not contain multiple binding sites for that miRNA. Genetic
variants in miRNA genes, biogenesis genes and target binding
sites associated with human diseases were recently reviewed by
Kawahara (2014). Here, we will focus on illustrating the diﬀerent
eﬀects genetic variants can have on miRNA transcription,
maturation, and targeting with examples from human miRNA
variants studied in disease where possible.
Variants Influencing miRNA Transcription or
Splicing
Though bio-informatics approaches have been used to predict
miRNA gene promoters (Saini et al., 2007; Marsico et al., 2013),
many miRNA gene promoters have not yet been experimentally
validated. Below we describe an example of a variant in a miRNA
promoter, which was experimentally delineated. The second
example is a case of a variant in a host gene promoter for an
intronic miRNA cluster. However, experimental investigation
of this type of variants can be complicated by the presence of
an independent miRNA promoter in addition to the host gene
promoter.
SNP rs57095329 is located in the promoter region of
MIR146A, 17 kb upstream of the pre-miR-146a sequence.
This variant was found to be associated with systemic lupus
erythematosus (SLE). The risk allele reduces the binding to
transcription factor Ets-1, another SLE susceptibility gene, and
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results in decreased promoter activity. Consistent with this mode
of action, risk allele carriers have lower expression of miR-146a-
5p (Luo et al., 2011).
SNP rs999885 is located in the promoter region of the
protein-coding gene MCM7. This variant was associated
with a decreased risk of chronic hepatitis B infection, but
also with an increased risk of hepatocellular carcinoma
(HCC) in individuals with chronic hepatitis B virus infection.
The miR-106b-25 cluster, coding for miR-106b, miR-93, and
miR-25, is located in the 13th intron of MCM7. HCC
patients that carry the risk allele have higher expression
of the miRNA transcript in non-tumor liver tissue than
non-carriers (Liu et al., 2012). Recently it was shown that
this cluster can be transcribed independently of MCM7
via diﬀerent promoters and that the miRNA polycistronic
transcript can undergo alternative splicing (Ramalingam et al.,
2014). Therefore it would be very interesting to uncover
whether and how this variant inﬂuences the relative and
absolute expression of the diﬀerent mature miRNAs in this
cluster.
To the best of our knowledge, variants in splice sites that aﬀect
miRNA expression in human disease have not been published yet.
Nevertheless, the eﬀect of host gene splice variants on mature
miRNA expression has been demonstrated by mutagenesis
experiments (Janas et al., 2011).
Variants Influencing miRNA Maturation
Variants within the pri-miRNA can aﬀect miRNA expression
levels by inducing changes in thematuration process, as described
above. This eﬀect can take place at several steps in the maturation
pathway: Drosha processing, Dicer processing, and/or altering
strand preference.
An example of a variant with and eﬀect on the Drosha
processing step is rs2910164. This variant is located in the
seed sequence of miR-146a-3p and was predicted to lead to
a mismatch in the hairpin stem. The heterozygous variant
genotype was associated with increased risk of papillary thyroid
carcinoma (PTC). After overexpression of pri-miR-146a with
the G allele or the C allele in cells, the C allele resulted in
nearly twofold reduction of pre-miR-146a compared to the
G allele. The reduced production of pre-miR-146a from pri-
miR-146a with a C allele was also conﬁrmed by an in vitro
processing assay (Jazdzewski et al., 2008). An example of a pri-
miRNA variant aﬀecting the ﬁrst processing step is a variant
located four bases upstream of the miR-510-5p sequence. This
variant was identiﬁed in a study screening X-linked miRNA
genes in male schizophrenia patients and control individuals.
The variant was predicted to alter the secondary structure
around the Drosha processing site. Functional validation showed
that the variant results in increased expression of pre-miR-510,
miR-510-5p, and miR-510-3p (Feng et al., 2009; Sun et al.,
2009).
A variant aﬀecting Dicer processing is rs546098287, located
within the seed sequence of miR-96-3p. This variant was
identiﬁed as the causative mutation in an Italian family
with non-syndromic hearing loss (Soldà et al., 2012). Two
segregating point mutations in miR-96-5p were previously
identiﬁed in two Spanish families with non-syndromic hearing
loss, demonstrating the importance of this gene in the disease
pathogenesis (Mencía et al., 2009). The mutation in miR-96-
3p reduces the processing from pre-miR-96 to both miR-96-5p
and miR-96-3p. This is likely induced by a structural change,
because the variant was predicted to enlarge an internal loop
in the hairpin stem and when a second variant was introduced
to restore the original stem structure, the expression was largely
brought back to normal levels (Soldà et al., 2012).
An example of a variant inﬂuencing the relative strand
abundance is a variant in MIR133A2, identiﬁed in a patient with
atrial ﬁbrillation. The variant is located at the 3′ end of the
miR-133a-3p sequence and was predicted to alter the secondary
structure of the hairpin at the base of the miR-133a duplex.
miR-133a was found to be highly expressed in atrial tissue,
with the 3p strand being the dominant one, while miR-133a-5p
represented less than 1% of all the miR-133a reads. Functional
validation experiments demonstrated that the variant resulted
in increased miR-133a-5p expression, but had no signiﬁcant
eﬀect on miR-133a-3p expression. The variant thus increases the
relative abundance of the 5p strand compared to the 3p strand
(Ohanian et al., 2013).
The cases described above are all variants located either within
the precursor sequence or close to it. A study by Diederichs
and Haber (2006) reported the functional validation of 15 pri-
miRNA variants ranging from 5 to 133 nt outside the pre-miRNA
sequence, identiﬁed in cancer cell lines. Despite some of these
variants had predicted structural changes at or near the base of
the miRNA hairpin, none of the variants displayed detectable
diﬀerences in mature miRNA expression. On the other hand,
for the variant rs11134527, which is located 96 nt outside the
MIR218-2 hairpin sequence, it was shown that it does change
the expression of miR-218-5p signiﬁcantly (Gao et al., 2013).
Therefore variants located further outside the hairpin can still
aﬀect miRNA biogenesis, although variants closer to the hairpin
are more likely to have a higher impact.
miRNA Variants Influencing Targeting
Beside resulting in altered expression, miRNA variants can also
result in altered target speciﬁcity by creating isomiRs.
An interesting example of a variant creating a polymorphic
isomiR is rs2910164 in miR-146a-3p. This variant also aﬀects
Drosha processing as described above (Jazdzewski et al., 2008).
The isomiR and canonical miR-146a-3p are predicted to share
only a small set of target genes. Transcriptome analysis in healthy
and in tumor tissue of PTC patients with GG or GC genotype
showed that hundreds of genes (358 in unaﬀected tissue, 575
genes in tumor tissue) were diﬀerentially expressed (Jazdzewski
et al., 2009). Even though this does not provide direct evidence
that all those genes are direct targets of the isomiR, it does
give insight in the large-scale downstream changes isomiRs may
induce.
Direct evidence of altered targeting was shown in a study
investigating the eﬀect of eight seed SNPs and three mature
sequence SNPs (among which one deletion) identiﬁed in dbSNP
in nine miRNA genes. Four of the tested miRNAs (miR-
627-5p, miR-379-5p, miR-499-3p, and miR-124-3p) partially or
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completely lost their potential to suppress their original target
due to a SNP in their seed sequence. The seed sequence variant
rs2620381 in miR-627-5p not only resulted in loss of targeting
of SEMA3F, but also in gained capacity to suppress ATP6V0E1
(Gong et al., 2012). In addition, miR-379-5p, miR-940, and miR-
34a-5p containing variants in the mature sequence also displayed
partial or total loss of function of their original mRNA targets
tested.
Studying miRNAs Involved in Disease
miRNA Profiling and Genetic Studies
To study if and which miRNAs play a role in the pathogenesis
of a disease, two main strategies can be used: a miRNA proﬁling
approach and a genetic approach.
In the miRNA proﬁling approach, the aﬀected tissue of a
group of patients is subjected to miRNA expression proﬁling
and compared to the expression proﬁle of either the same tissue
in healthy individuals, tissue of patients with a diﬀerent disease
or subphenotype, or to adjacent non-aﬀected tissue of the same
patients (Calin et al., 2005; Kan et al., 2012; Feliciano et al.,
2013; Huang et al., 2014). The tested miRNAs can range from
selected candidate miRNAs to a genome-wide approach and
diﬀerent technologies are available, such as RT-qPCR, microarray
based methods or RNA sequencing (Pritchard et al., 2012). The
miRNA expression proﬁles are compared between the disease
phenotype and the controls in order to determine whether and
which miRNAs are diﬀerentially expressed. Resulting signatures
may be used as diagnostic or prognostic biomarkers (Calin
and Croce, 2006) and can provide clues about the role of
miRNAs in the disease mechanism. Additionally, interesting
miRNAs can be further investigated to dissect their mode of
action.
In the genetic approach, the starting point is a linkage
or an association analysis (genome-wide or candidate gene
approach) including but not necessarily limited to miRNA genes
between patients and control individuals (Mencía et al., 2009;
Schizophrenia Psychiatric Genome-Wide Association Study
(GWAS) Consortium, 2011; Zhang et al., 2015). When a genetic
variant in or near a miRNA gene is associated with or is causal
for the disease, functional validation can be initiated to assess its
eﬀect and its role in the pathogenesis of the disease. Variants in
miRNA genes linked to the disease could also be used for disease
diagnosis, as exempliﬁed by the patent on rare miRNA gene
variants identiﬁed in schizophrenia patients (Sommer and Rossi,
2012). The genetic screening approach focused on miRNA genes
is not yet as frequently applied on a large scale as genome-wide
miRNA proﬁling.
Both strategies have limitations and beneﬁts. General
considerations regarding miRNA proﬁling were reviewed by
Pritchard et al. (2012). In the study of disease, genome-wide
miRNA proﬁling can provide a global insight in which miRNAs
may play a role in the disease by generating disease-speciﬁc
miRNA expression signatures. An advantage of this approach
is that the deregulated miRNA provides a ﬁrst indication of
its possible functional role in the disease. The main limitation,
however, is that the diﬀerential expression of a miRNA in
itself does not provide an indication of causality: the altered
expression can be a causal factor, a consequence, or could even be
unrelated to the disease pathogenesis (Kan et al., 2012). Another
constraint is that the aﬀected tissue has to be accessible. This
is especially problematic in the study of neurological diseases.
Alternatively, brain tissue of deceased patients and healthy
individuals, if available, can be used. However, though many
miRNAs seem to be relatively stable (Bail et al., 2010; Winter and
Diederichs, 2011), the half-lives of some miRNAs are less than
1 hour (Sethi and Lukiw, 2009). This implicates that when brain
samples with diﬀerent postmortem delay from death to tissue
processing are compared, variability may arise due to diﬀerential
instability of the miRNAs in the samples. The restricted access
to postmortem brain samples can also result in suboptimal
sample sizes. A much more accessible proxy for unavailable
aﬀected tissues is blood. While this may provide a good avenue
for determining diagnostic or prognostic biomarkers, it is not
clear whether the miRNAs deregulated in blood would also be
deregulated in the aﬀected tissue. In addition, several factors can
inﬂuence miRNA expression in blood, such as age, drug use, and
other diseases (Margis et al., 2011; de Boer et al., 2013; Meder
et al., 2014).
The main advantage of a genetic approach is that when a
variant is associated with disease risk, it gives an indication
that the miRNA involved has a primary eﬀect in the disease
pathomechanism (large or small contributing eﬀect), which
cannot be determined by expression proﬁling. This advantage
also has a downside: while the association or linkage analysis
may indicate a miRNA variant is likely to be involved in the
disease, it is not at all clear whether the identiﬁed variant has
a functional eﬀect and whether the expression of that miRNA
is altered in the disease state. Another asset of the genetic
approach is that diseases for which the main aﬀected tissue is
not accessible can still be studied because genomic DNA can be
isolated from more accessible patient material, such as blood or
saliva. There is, however, still a chance of missing a mutation,
if the patient is mosaic for the mutation and the load of the
mutation is lower in the examined tissue than in the aﬀected
tissue.
Both approaches are complementary and should both be
used to determine the involvement of a miRNA in relation
to a disease: genetic approaches can pinpoint the causal or
risk factors involved in the disease, while expression studies
reveal whether and how the expression of the disease-associated
miRNAs is altered in the aﬀected tissue. Neither approach is
suﬃcient to determine both. An example of a study combining
both approaches is the study of Calin et al. (2005) where miRNA
proﬁling in aﬀected tissue of patients was performed, followed by
variant screening in a set of relevantmiRNA genes. An expression
signature of thirteen miRNA genes was found to be able to
distinguish between patient subgroups. In two of these genes,
patient-speciﬁc variants were found. One of the variants was a
functional germline mutation in pri-miR-15a/16-1. On the other
hand, when a genetic variant is associated with a disease, usually
only the expression of that particular miRNA is assessed in
patient material. The proﬁling and genetic approach has also been
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combined on a large scale by miRNA proﬁling in blood samples
of patients with diﬀerent diseases and investigating whether
the deregulated miRNA genes were located within 250 kb of
published GWAS signiﬁcant SNPs (Keller et al., 2011). While on
average 103 deregulated miRNAs were identiﬁed in each disease,
of all the deregulated miRNAs they found only six miRNA genes
in proximity to a GWAS hit associated with the same disease.
Combining the genetic and the proﬁling approach on the same
set of patients could thus provide an invaluable amount of
information on both DNA and RNA level fromwhich the disease-
contributing miRNAs can be separated from the miRNAs that are
probably deregulated due to secondary disease processes.
Databases and Tools for Genetic
Approaches
To provide direct evidence that a genetic variant in or
near a miRNA gene and the deregulated miRNA expression
in disease tissue are linked, detailed functional validation is
required. Functional validation is labor-intensive, costly, and
time-consuming, therefore researchers usually prioritize the
potential candidate variants using in silico approaches. In this
section, we will focus on available databases and tools for
the impact prediction of genetic variants on miRNA function
(Tables 1 and 2). Diﬀerent types of resources for miRNA research
have been reviewed by Vlachos and Hatzigeorgiou (2013).
A ﬁrst step in the assessment of the relevance of a genetic
variant or a set of genetic variants is determining whether the
variant is located near or in a speciﬁc region of a miRNA gene.
For a single variant of interest, the variant location may be
assessed in a genome browser to determine the position of the
variant compared to neighboring miRNA genes. To evaluate the
exact location of the variant relative to the diﬀerent miRNA
gene regions (e.g., seed, mature, terminal loop), one also has
to compare this location with the information provided about
the gene in miRBase (Kozomara and Griﬃths-Jones, 2014).
This procedure is tedious and error-prone, especially when
investigating multiple miRNA variants. For variant lists such as
those derived from massively parallel sequencing projects, the
ﬁrst annotation step can be done with any of the annotation tools
available to determine which (miRNA) genes, if any, are located
near the variants.
Online repositories compiling information about known SNPs
in miRNA genes, such as miRNASNP (Gong et al., 2012), miRNA
SNiPer (Zorc et al., 2015), and miRvar (Bhartiya et al., 2011), can
be used to extract exact location information for these variants
relative to the miRNA hairpin. A limitation for the last two
databases is that the search needs to be initiated by using the
miRNA gene name instead of the SNP ID. In addition, databases
cannot be used when investigating novel variants and are less
suitable when investigating multiple variants in several miRNA
genes. To eliminate the time-consuming processes related to
assessing the position of variants in the context of miRNA
genes and what their predicted structural impact is, we recently
developed the freely available software miRVaS1. Required input
is the genomic location of a (known or novel) variant or of a list
of variants.
The next possible step in determining the potential relevance
of a genetic variant is predicting its eﬀect on the secondary
structure of the miRNA. For known SNPs within miRNA genes,
structure prediction results of the miRNA hairpin with and
without the variant can be found in the miRNASNP database
(Gong et al., 2012). The diﬀerence in free energy is calculated
and a predicted eﬀect on the miRNA expression is provided,
based on the assumption that variants destabilizing the hairpin
1http://mirvas.bioinf.be/
TABLE 1 | Overview of described databases.
Name Use URL
miRBase Database for miRNA sequences and gene annotations http://www.mirbase.org/
miRNASNP Database for miRNA gene variants, location annotation, RNA secondary structure
impact prediction, target impact prediction for seed variants
http://bioinfo.life.hust.edu.cn/miRNASNP2/index.php
miRNA SNiPer Database for miRNA gene variants, location annotation http://www.integratomics-time.com/miRNA-SNiPer/
miRvar Database for miRNA gene variants, location annotation, predicted impact on Dicer
and RISC loading
http://genome.igib.res.in/mirlovd/home.php
PolymiRTS Database Database with miRNA seed variants and predicted effect on targeting http://compbio.uthsc.edu/miRSNP/
dPORE-miRNA Database with miRNA promoter variants and their predicted effect on transcription
binding
http://cbrc.kaust.edu.sa/dpore/
The Use column refers to the usage described in the text. Most of the databases also incorporate other information not mentioned here.
TABLE 2 | Overview of described software.
Name Use URL
miRVaS Location annotation, RNA secondary structure impact
prediction for miRNA gene variants
http://mirvas.bioinf.be/
Mfold RNA secondary structure prediction http://mfold.rna.albany.edu/
RNAfold RNA secondary structure prediction http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi
PHDcleav Prediction of Dicer processing sites http://www.imtech.res.in/raghava/phdcleav/
RISC binder Prediction of preferential strand loaded into RISC http://crdd.osdd.net:8081/RISCbinder/
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will reduce the expression and stabilizing variants will increase
the expression of the mature miRNA (Gong et al., 2012). For
novel variants the RNA secondary structures can be predicted for
wild type and variant sequences using web-based RNA structure
prediction tools, such as the Mfold or RNAfold web servers
(Zuker, 2003; Gruber et al., 2008), and compared. Again, this
process is time-consuming and not suitable for the analysis
of large variant sets. miRVaS1 automates this type of analysis,
predicting structural impact for lists of variants, needing only the
genomic location and alternative allele of the variant.
If a variant is located in a miRNA seed sequence, the eﬀect
on target binding can also be assessed in silico. Both PolymiRTS
database (Bhattacharya et al., 2014) and miRNASNP (Gong
et al., 2012) contain lists of predicted gain and loss of target
binding sites for seed sequence variants that can be browsed.
To assess the impact of variants in miRNA promoter regions
on transcription factor binding, the dPORE-miRNA database
can be queried (Schmeier et al., 2011). Algorithms to predict
Dicer cleavage patterns and preferential strand loading into
RISC, such as PHDcleav and RISC binder (Ahmed et al., 2009,
2013) could also be useful to assess the impact of variants.
The predicted eﬀect on Dicer cleavage and RISC binding
induced by variants is incorporated in the miRvar database
(Bhartiya et al., 2011).
Functional Characterization of a
Disease-Associated miRNA Variant
Using tools and databases, a set of genetic variants can be
prioritized based on their potential functional relevance. The
most promising candidates can then be chosen for direct
functional validation in cell-based assays. The assays used depend
on the location of the variant and the hypothesis.
For variants in miRNA promoter regions, the wild type and
variant promoter can be cloned into a promoter-less reporter
gene vector and transfected (transiently or stably) into cell lines to
assess whether there is a diﬀerence in promoter activity due to the
variant and whether the variant promoter has diﬀerent binding
aﬃnity to transcription factors (Luo et al., 2011).
To assess the impact of a genetic variant on miRNA biogenesis
and/or targeting, cell lines overexpressing wild type and mutant
miRNAs are usually established. The constructs should include
the full precursor gene and upstream and downstream ﬂanking
sequences. The inclusion of ﬂanking regions is crucial: the
biogenesis machinery in the cell may not eﬃciently recognize
or process the transcript when the ﬂanking regions are absent
or too small, as evidenced by the study of Chen et al. (2004)
where only constructs for miR-223 with at least 40 nt of ﬂanking
region resulted in detectable miR-223 expression. Using up-
and downstream ﬂanks of 125 nt resulted in mature miRNA
expression for all 13 tested miRNAs in this study, showing
that the incorporation of longer ﬂanks in miRNA constructs
is generally a good strategy. To assess the eﬀect on biogenesis,
miRNA expression analysis is performed. Comparison of wild
type and variant miRNA levels can be done at the level of the
mature miRNA (Shen et al., 2009), assessing the total eﬀect of
the variant on the whole biogenesis process, or it can be done
on several maturation levels of the miRNA, to deduce the exact
step of the biogenesis that is aﬀected by the variant (Duan et al.,
2007).
If a variant is located in the maturemiRNA sequence, targeting
may be aﬀected. Investigating which genes and pathways are
aﬀected due to the variant may provide insight in the disease
mechanism by identifying new pathways and/or by conﬁrming
pathways previously hypothesized to be involved in the disease.
Investigation and validation of direct interactions between
miRNA and target RNAs can be done using reporter assays.
Hereto, the potential binding site is cloned downstream of a
reporter gene and cells are cotransfected with the miRNA and
the reporter vector to assess whether the miRNA (or the variant
miRNA) can target the site and thus reduce the reporter gene
activity (Duan et al., 2007; Gong et al., 2012). While this allows
conﬁrmation of direct interactions, overexpression of the binding
site and the miRNA may also lead to validation of interactions
that may not take place endogenously in the cell type or tissue
of interest, due to, for instance, absence of colocalization, or
co-expression.
Investigation of variant induced targeting alterations can also
be performed on a large scale by subjecting the wild type
and variant miRNA expressing cells to transcriptome and/or
proteome proﬁling. Single genes or proteins can be analyzed
for diﬀerential expression. Pathway analysis can also identify
which set of genes are inﬂuenced by the variant miRNA and
may lead to biological meaningful ﬁndings about the variant
miRNA and the pathways in the cell it aﬀects in the disease state
(Jazdzewski et al., 2009). If a variant is located outside the mature
miRNA sequence, this approach can still be used if the variant
aﬀects mature miRNA expression, as the altered expression of the
miRNA will also deregulate its target genes (Strazisar et al., 2015).
However, in contrast to the reporter gene assays, these large-scale
approaches cannot distinguish between direct and indirect targets
of the miRNA, so target prediction algorithms need to be used
to determine which of the deregulated genes can potentially be
targeted directly by the miRNA.
Diﬀerent crosslinking and immunoprecipitation (CLIP)
approaches were developed and applied for global miRNA–RNA
target interaction identiﬁcation by Argonaute precipitation, such
as HITS-CLIP and PAR-CLIP (Ule et al., 2005; Chi et al., 2009;
Hafner et al., 2010). In these methods, RNA and proteins are
crosslinked in cells by UV irradiation (in case of PAR-CLIP after
incorporation of photoactivatable nucleosides). After cell lysis
and partial RNA digestion, Argonaute-RNA complexes are pulled
down and puriﬁed stringently. Subsequently, coprecipitated
RNA is sequenced to identify which miRNAs and which target
RNA regions were bound to Argonaute. Because miRNA and
target RNAs are not physically linked to each other during
the procedure, in silico target prediction is required to assess
the interactions between the identiﬁed RNA sequences. These
approaches thus provide enrichment for actual target RNA sites
bound to Argonaute and limits the target prediction to these sites
and to the detected miRNAs.
A method that can identify direct miRNA-target interactions
on a large scale is the crosslinking, ligation, and sequencing of
hybrids (CLASH) technology (Kudla et al., 2011; Helwak et al.,
2013). Similar to the CLIP techniques, cells are UV irradiated
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to mediate crosslinking, after which Argonaute-RNA complexes
are pulled down and RNA is partially digested. Then a ligation
step is performed to ligate miRNAs to their target RNAs. The
RNA is sequenced to identify chimeric RNAs. The non-chimeric
reads provide the same information as the CLIP experiments,
while the chimeric RNAs contain linked miRNA and target
RNA fragments and hence provide direct proof of miRNA-target
interactions. This technology may thus be used to directly identify
whether mature miRNA variants alter targeting capacity of a
disease-associated miRNA.
Together, these approaches can be used to assess what the
eﬀect of the genetic variant is on the expression and the
functionality of the miRNA.
Concluding Remarks
In this review we summarized the current knowledge of the
miRNA maturation process, focusing on the prerequisites of the
miRNA transcript to be processed. From these requirements
it is clear that the RNA structure, and thus also the
underlying sequence determining the structure, are of paramount
importance for maturation into mature miRNAs. Thus genetic
variants in miRNA genes can have large eﬀects, not only on
the miRNA gene itself, but due to its role as a ﬁne-tuner of
gene expression and translation, also on its downstream targets.
In line with this, diﬀerent miRNA variants have been found to
be involved or hypothesized to be involved in human disease.
We also highlighted the biological relevance of genetic variants
located within or near miRNA genes and provided an overview
of in silico and experimental approaches to investigate the eﬀect
of these variants on miRNA expression and function. This in
turn could then be correlated to changes in miRNA and target
gene abundance in the aﬀected tissue of patients, as a ﬁrst step
in the understanding of the role of the miRNA in the disease
pathomechanism.
As we are now coming to realize that the miRNA repertoire
is much more complex than previously appreciated with the
recognition of the wide-spread presence of isomiRs and their
functional relevance, the possibilities of intronic miRNAs being
transcribed independently from their host genes and even
alternative splicing, many more questions arise. Though many
aspects of miRNA biogenesis and functioning have already been
unraveled, more investigations will need to be done to be able
to fully grasp the regulation and the genesis of the correct
expression pattern of the full miRNA repertoire in the cell. We
also anticipate that, especially for the investigation of genetic
variants in disease, we will need to undertake comprehensive
and integrative approaches to be able to fully appreciate
how certain genetic variants can undermine this regulatory
system and lead to disease, while others remain completely
harmless.
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